Macrophage activation syndrome and other systemic inflammatory conditions after BMT

Bone Marrow Transplant. 2006 Apr;37(7):629-34. doi: 10.1038/sj.bmt.1705305.

Abstract

Autologous hematopoietic cell transplantation (HCT) is being used to treat autoimmune diseases refractory to conventional therapy, including rheumatoid arthritis. Macrophage activation syndrome (MAS) is a descriptive term for a systemic inflammatory disorder that has been described in patients with juvenile rheumatoid arthritis (JRA). This case report describes a young adult with systemic JRA (sJRA) who developed MAS on day # 12 post-autologous transplantation. The patient developed high fever, laboratory evidence of disseminated intravascular coagulation (DIC), hepatocellular injury, pancytopenia and hyper-ferritinemia. All viral, bacterial and fungal studies were negative and the patient improved with high-dose glucocorticosteroid and cyclosporine therapy. Extreme elevation of serum ferritin was documented and helpful in monitoring response to therapy. A number of systemic inflammatory syndromes have been described in association with HCT. These include DIC, 'engraftment syndrome,' infection-associated hemophagocytic syndrome and familial hemophagocytic lymphohistiocytosis. Macrophage activation syndrome presents with features of DIC and is closely related or identical to infection-associated hemophagocytic syndrome. The diagnosis needs to be established in a timely fashion because early and appropriate treatment may improve outcome.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Arthritis, Juvenile / diagnosis
  • Arthritis, Juvenile / immunology
  • Arthritis, Juvenile / therapy
  • Autoimmune Diseases / etiology
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Inflammation / immunology
  • Macrophage Activation / immunology*
  • Macrophages / immunology*
  • Male
  • Remission Induction
  • Syndrome